STOCK TITAN

Illumina To Webcast Upcoming Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:

  • Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021
    Fireside Chat at 7:30 am Pacific Time / 10:30 am Eastern Time

The live webcast can be accessed under the Investor Info section of the "company" tab at www.illumina.com. A replay will be posted on Illumina’s website after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

Illumina Inc

NASDAQ:ILMN

ILMN Rankings

ILMN Latest News

ILMN Stock Data

Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Analytical Laboratory Instrument Manufacturing
US
San Diego

About ILMN

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.